CA3164914A1 - Dosing regimens and methods for treating cancer - Google Patents
Dosing regimens and methods for treating cancer Download PDFInfo
- Publication number
- CA3164914A1 CA3164914A1 CA3164914A CA3164914A CA3164914A1 CA 3164914 A1 CA3164914 A1 CA 3164914A1 CA 3164914 A CA3164914 A CA 3164914A CA 3164914 A CA3164914 A CA 3164914A CA 3164914 A1 CA3164914 A1 CA 3164914A1
- Authority
- CA
- Canada
- Prior art keywords
- 2dehspm
- cancer
- treatment
- patient
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062963492P | 2020-01-20 | 2020-01-20 | |
| US62/963,492 | 2020-01-20 | ||
| PCT/US2021/014112 WO2021150559A1 (en) | 2020-01-20 | 2021-01-20 | Dosing regimens and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3164914A1 true CA3164914A1 (en) | 2021-07-29 |
Family
ID=76992702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3164914A Pending CA3164914A1 (en) | 2020-01-20 | 2021-01-20 | Dosing regimens and methods for treating cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230064990A1 (https=) |
| EP (1) | EP4093386A4 (https=) |
| JP (1) | JP2023512487A (https=) |
| AU (1) | AU2021210867A1 (https=) |
| CA (1) | CA3164914A1 (https=) |
| WO (1) | WO2021150559A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026501282A (ja) * | 2022-12-20 | 2026-01-14 | ジェネンテック, インコーポレイテッド | Pd-1軸結合アンタゴニストおよびrnaワクチンを用いて膵臓がんを処置する方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6160022A (en) * | 1999-07-19 | 2000-12-12 | University Of Florida | Chemical resection of pancreas |
| US20130137772A1 (en) * | 2011-11-29 | 2013-05-30 | Raymond J. Bergeron | Hydroxypolyamine salts |
| WO2017062704A1 (en) * | 2015-10-08 | 2017-04-13 | Sun Biopharma, Inc. | Compositions and methods for treating pancreatitis |
| US10195188B2 (en) * | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| EP4257581A1 (en) * | 2018-01-30 | 2023-10-11 | Panbela Therapeutics, Inc. | Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol |
-
2021
- 2021-01-20 JP JP2022543648A patent/JP2023512487A/ja active Pending
- 2021-01-20 CA CA3164914A patent/CA3164914A1/en active Pending
- 2021-01-20 WO PCT/US2021/014112 patent/WO2021150559A1/en not_active Ceased
- 2021-01-20 AU AU2021210867A patent/AU2021210867A1/en active Pending
- 2021-01-20 EP EP21744163.3A patent/EP4093386A4/en not_active Withdrawn
-
2022
- 2022-07-18 US US17/866,876 patent/US20230064990A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4093386A1 (en) | 2022-11-30 |
| EP4093386A4 (en) | 2024-01-10 |
| AU2021210867A1 (en) | 2022-08-18 |
| WO2021150559A1 (en) | 2021-07-29 |
| US20230064990A1 (en) | 2023-03-02 |
| JP2023512487A (ja) | 2023-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11980652B2 (en) | Compositions and methods for subcutaneous administration of cancer immunotherapy | |
| WO2019124500A1 (ja) | Tlr7アゴニストを含む併用薬 | |
| KR20170002410A (ko) | 종양 유도 면역 반응의 효능을 향상시키는 방법 | |
| US20250032582A1 (en) | Compositions and methods for cancer immunotherapy | |
| US20230064990A1 (en) | Dosing regimens and methods for treating cancer | |
| AU2021257874A1 (en) | Immunostimulatory agents in combination with angiogenesis inhibitors | |
| US20230181633A1 (en) | Methods of treating cancer using a combination of tumor membrane vesicles and metformin | |
| WO2025207491A1 (en) | Compositions and methods for cancer immunotherapy | |
| US20210338656A1 (en) | Immunostimulatory agents in combination with angiogenesis inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220926 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240819 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241206 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250115 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250115 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250115 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250204 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250605 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250605 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20251217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251222 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251223 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260305 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260318 |